medroxyprogesterone acetate has been researched along with Obesity in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.78) | 18.7374 |
| 1990's | 2 (5.56) | 18.2507 |
| 2000's | 16 (44.44) | 29.6817 |
| 2010's | 15 (41.67) | 24.3611 |
| 2020's | 2 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Abd Jamil, AH; Chung, I; Mat Adenan, NA; Omar, IS | 1 |
| Kassahun-Yimer, W; Lutz, E; Ngwudike, C; Shwayder, J; Sims, J; Wallace, K | 1 |
| Jiang, S; Kuang, Y | 1 |
| Brynhildsen, J; Forslund, I; Ginstman, C; Månsson, A; Sundell, M | 1 |
| Curtis, KM; Folger, SG; Morgan, IA; Whiteman, MK; Zapata, LB | 1 |
| Diamond, K; Nickkho-Amiry, M; Seif, MW | 1 |
| Bi, Y; Chen, M; Jin, Y; Li, Y; Pan, L; Shan, Y | 1 |
| Dragoman, MV; Gaffield, ME | 1 |
| Curtis, KM; Folger, SG; Jamieson, DJ; Jatlaoui, TC; Mandel, MG; Marchbanks, PA; Zapata, LB | 1 |
| Baskan, B; Demir, B; Haberal, A; Kandemir, O; Karabulut, E; Ozturkoglu, E; Solaroglu, A | 1 |
| Emans, SJ; Pitts, SA | 1 |
| Baccarin, MC; Bahamondes, L; Fernandes, AM; Medeiros, T; Morais, SS; Pantoja, M | 1 |
| Weisberg, E | 1 |
| Azen, S; Liu, X; Mishell, DR; Segall-Gutierrez, P; Stanzcyk, F; Taylor, D | 1 |
| Gerlach, LS; Nick, TG; Saldaña, SN; Spigarelli, MG; Wang, Y | 1 |
| Buchanan, TA; Jurow, R; Liu, X; Segall-Gutierrez, P; Stanczyk, FZ; Trigo, E; Watanabe, RM; Xiang, AH | 1 |
| Archer, DF; Oger, E | 1 |
| Du, J; Ge, M; Mizraji, K; Niu, C; Segall-Gutierrez, P; Stanczyk, FZ; Tilley, I | 1 |
| Habash, DL; Nyirati, CM; Shaffer, LE | 1 |
| Ahn, JY; Choi, IS; Jin, DK; Kim, DS; Kim, HS; Koh, KK; Shin, EK; Shin, MS; Son, JW; Yoon, BK | 1 |
| Hulley, SB; Ireland, CC; Kuppermann, M; Learman, LA; Richter, HE; Summitt, RL; Varner, RE; Vittinghoff, E; Washington, E | 1 |
| Bonny, AE; Britto, MT; Huang, B; Slap, GB; Succop, P | 1 |
| Alderman, EL; Howard, BV; Hsia, J; Lindsay, J; Ouyang, P; Silverman, A; Tripputi, M; Van Voorhees, L; Waters, DD | 1 |
| Amezcua, C; Bahador, A; Burnett, AF | 1 |
| Barrett-Connor, E; Bibbins-Domingo, K; Grady, D; Hulley, SB; Lin, F; Shlipak, MG; Vittinghoff, E | 1 |
| Cushman, M; Kuller, LH; Prentice, R; Psaty, BM; Rodabough, RJ; Rosendaal, FR; Sidney, S; Stafford, RS | 1 |
| Artini, PG; Battaglia, C; de Aloysio, D; Mancini, F; Persico, N; Regnani, G; Volpe, A | 1 |
| Kim, CJ; Ko, HS; Ryu, WS | 1 |
| Bonny, AE; Cromer, BA; Harkness, LS | 1 |
| Kuhl, H; Stevenson, J | 1 |
| Atlas, M; Gordon, L; Januchowski, R; Thakur, N | 1 |
| Liu, S; Margolis, KL; Tinker, LF; Ye, W; Zheng, Z | 1 |
| Clarkson, TB; Shively, CA; Wallace, JM | 1 |
| Campana, A; Chmouliovsky, L; Golay, A; Habicht, F; James, RW; Lehmann, T | 1 |
| Hudson, S; Larsen, PG; Mangan, SA | 1 |
| Aizawa, M; Houjou, T; Kadota, K; Kurooka, K; Matunami, N; Mori, N; Morikawa, E; Nakano, K; Wada, T; Yamato, M | 1 |
6 review(s) available for medroxyprogesterone acetate and Obesity
| Article | Year |
|---|---|
Obesity and menstrual disorders.
Topics: Amenorrhea; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Endometrial Ablation Techniques; Endometrial Hyperplasia; Estrogens; Female; Humans; Hysterectomy; Intrauterine Devices, Medicated; Medroxyprogesterone Acetate; Menorrhagia; Menstruation Disturbances; Obesity; Oligomenorrhea; Prevalence; Progestins | 2015 |
The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
Topics: Bone Density; Contraceptive Agents, Female; Delayed-Action Preparations; Endometriosis; Female; HIV Infections; Humans; Injections, Intramuscular; Injections, Subcutaneous; Medroxyprogesterone Acetate; Obesity; Pain; Patient Satisfaction; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Weight Gain; World Health Organization | 2016 |
Controversies in contraception.
Topics: Adolescent; Contraception; Contraceptive Agents, Female; Female; Humans; Hypertension; Medroxyprogesterone Acetate; Migraine Disorders; Obesity; Osteoporosis; Venous Thromboembolism; Weight Gain | 2008 |
Retrospective review of the relationship between weight change and demographic factors following initial depot medroxyprogesterone acetate injection in adolescents.
Topics: Adolescent; Child; Contraceptive Agents; Delayed-Action Preparations; Humans; Injections, Intramuscular; Linear Models; Medroxyprogesterone Acetate; Menarche; Obesity; Retrospective Studies; Weight Gain | 2011 |
Estrogen and progestogen effect on venous thromboembolism in menopausal women.
Topics: Administration, Cutaneous; Age Factors; Aged; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Obesity; Postmenopause; Progestins; Risk Factors; Venous Thrombosis; Women's Health | 2012 |
Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female.
Topics: Adolescent; Body Composition; Bone Density; Clinical Trials as Topic; Contraceptive Agents, Female; Cross-Cultural Comparison; Female; Humans; Medroxyprogesterone Acetate; Obesity; Patient Dropouts; Pregnancy; Pregnancy in Adolescence; Risk Factors; Weight Gain | 2005 |
10 trial(s) available for medroxyprogesterone acetate and Obesity
| Article | Year |
|---|---|
The effects of estrogen therapy and estrogen combined with different androgenic progestins on carbohydrate and lipid metabolism in overweight-obese younger postmenopausal women.
Topics: Blood Glucose; Carbohydrate Metabolism; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Female; Humans; Insulin Resistance; Lipid Metabolism; Medroxyprogesterone Acetate; Nandrolone; Norethindrone; Norethindrone Acetate; Obesity; Progesterone Congeners; Prospective Studies | 2008 |
Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously.
Topics: Adult; Body Mass Index; Contraceptive Agents, Female; Delayed-Action Preparations; Estradiol; Female; Humans; Immunoassay; Injections, Subcutaneous; Medroxyprogesterone Acetate; Obesity; Obesity, Morbid; Ovarian Follicle; Ovulation; Ovulation Inhibition; Progesterone; Progestins; Severity of Illness Index; Young Adult | 2010 |
Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use.
Topics: Adult; Biomarkers; Cardiovascular Diseases; Contraceptive Agents, Female; Female; Humans; Insulin Resistance; Medroxyprogesterone Acetate; Obesity; Pregnancy; Prospective Studies; Risk Factors; Young Adult | 2012 |
Effect of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women.
Topics: Adult; Androgen Antagonists; Androgens; Androstane-3,17-diol; Androstenedione; Biomarkers; Body Mass Index; Contraceptive Agents, Female; Dehydroepiandrosterone Sulfate; Drug Implants; Female; Humans; Medroxyprogesterone Acetate; Obesity; Obesity, Morbid; Sex Hormone-Binding Globulin; Subcutaneous Tissue; Testosterone; Time Factors; Young Adult | 2012 |
Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women.
Topics: Animals; Biomarkers; Brachial Artery; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Estrogens, Conjugated (USP); Female; Hormone Replacement Therapy; Horses; Humans; Hypertension; Inflammation; Lipids; Medroxyprogesterone Acetate; Middle Aged; Obesity; Postmenopause; Progesterone; Progesterone Congeners; Regional Blood Flow; Vasomotor System | 2002 |
Medicine or Surgery (Ms): a randomized clinical trial comparing hysterectomy and medical treatment in premenopausal women with abnormal uterine bleeding.
Topics: Adult; Black or African American; Contraceptives, Oral; Costs and Cost Analysis; Cyclooxygenase Inhibitors; Female; Humans; Hysterectomy; Medroxyprogesterone Acetate; Middle Aged; Obesity; Patient Selection; Premenopause; Quality of Life; Uterine Hemorrhage | 2004 |
Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance.
Topics: Adult; Aged; Blood Glucose; C-Reactive Protein; Canada; Comorbidity; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Drug Combinations; Estrogens, Conjugated (USP); Female; Fibrinogen; Follow-Up Studies; Glucose Intolerance; Hormone Replacement Therapy; Humans; Hysterectomy; Inflammation; Insulin; Insulin Resistance; Lipoproteins, HDL; Medroxyprogesterone Acetate; Middle Aged; Obesity; Postmenopause; Prospective Studies; Single-Blind Method; Triglycerides; United States | 2004 |
Estrogen plus progestin and risk of venous thrombosis.
Topics: Age Factors; Aged; Blood Coagulation Factors; Body Mass Index; Case-Control Studies; Double-Blind Method; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Factor V; Female; Follow-Up Studies; Humans; Incidence; Medroxyprogesterone Acetate; Middle Aged; Obesity; Postmenopause; Proportional Hazards Models; Risk; Venous Thrombosis | 2004 |
Overweight and effect of hormone replacement therapy on lipid profiles in postmenopausal women.
Topics: Contraceptive Agents, Female; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Lipoproteins; Medroxyprogesterone Acetate; Middle Aged; Obesity; Postmenopause | 2005 |
Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux.
Topics: Aged; Body Mass Index; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Gastroesophageal Reflux; Humans; Hysterectomy; Incidence; Medroxyprogesterone Acetate; Middle Aged; Obesity; Risk; Risk Factors; Waist-Hip Ratio | 2008 |
20 other study(ies) available for medroxyprogesterone acetate and Obesity
| Article | Year |
|---|---|
MPA alters metabolic phenotype of endometrial cancer-associated fibroblasts from obese women via IRS2 signaling.
Topics: Acetates; Cancer-Associated Fibroblasts; Endometrial Neoplasms; Female; Glucose; Humans; Insulin Receptor Substrate Proteins; Medroxyprogesterone Acetate; Mifepristone; Neoplasm Recurrence, Local; Obesity; Phenotype; Progesterone; Receptors, Progesterone; RNA, Messenger | 2022 |
Depo-medroxyprogesterone acetate, weight gain and amenorrhea among obese adolescent and adult women.
Topics: Adolescent; Adult; Age Factors; Amenorrhea; Body Mass Index; Contraceptive Agents, Female; Female; Humans; Injections, Intramuscular; Medroxyprogesterone Acetate; Obesity; Retrospective Studies; Time Factors; Weight Gain; Young Adult | 2020 |
Clomiphene citrate is associated with favorable cycle characteristics but impaired outcomes of obese women with polycystic ovarian syndrome undergoing ovarian stimulation for in vitro fertilization.
Topics: Academic Medical Centers; Adult; Clomiphene; Female; Fertility Agents, Female; Fertilization in Vitro; Humans; Infertility, Female; Medroxyprogesterone Acetate; Menotropins; Obesity; Oocytes; Ovulation Induction; Polycystic Ovary Syndrome; Retrospective Studies | 2017 |
Patterns of prescription and discontinuation of contraceptives for Swedish women with obesity and normal-weight women.
Topics: Adolescent; Adult; Contraception; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Drug Prescriptions; Female; Humans; Ideal Body Weight; Intrauterine Devices, Copper; Medication Adherence; Medroxyprogesterone Acetate; Menstruation Disturbances; Obesity; Practice Guidelines as Topic; Progestins; Retrospective Studies; Sweden; Young Adult | 2019 |
Changes in US health care provider attitudes related to contraceptive safety before and after the release of National Guidance.
Topics: Attitude of Health Personnel; Contraception; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Cross-Sectional Studies; Evidence-Based Medicine; Family Planning Services; Female; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; Intrauterine Devices, Medicated; Male; Medroxyprogesterone Acetate; Obesity; Practice Guidelines as Topic; United States | 2019 |
Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; China; Disease-Free Survival; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility; Fertility Preservation; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Recurrence, Local; Obesity; Pregnancy; Progestins; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Healthcare Provider Attitudes Regarding Contraception for Women with Obesity.
Topics: Adult; Attitude of Health Personnel; Contraception; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Family Planning Services; Female; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; Intrauterine Devices, Medicated; Medroxyprogesterone Acetate; Obesity | 2017 |
Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive.
Topics: Adult; Analysis of Variance; Body Mass Index; Body Weight; Cohort Studies; Contraceptive Agents, Female; Female; Humans; Intrauterine Devices, Copper; Medroxyprogesterone Acetate; Obesity; Overweight; Retrospective Studies; Weight Gain | 2010 |
Contraceptive options for women in selected circumstances.
Topics: Adolescent; Adult; Anemia; Breast Diseases; Cardiovascular Diseases; Condoms; Contraception; Contraceptive Agents, Female; Contraindications; Desogestrel; Diabetes Mellitus; Drug Combinations; Drug Implants; Epilepsy; Ethinyl Estradiol; Female; Heart Valve Diseases; Humans; Hypertension; Inflammatory Bowel Diseases; Injections; Intrauterine Devices; Levonorgestrel; Liver Diseases; Lupus Erythematosus, Systemic; Medroxyprogesterone Acetate; Migraine Disorders; Norethindrone; Norgestrel; Obesity; Patient Preference; Pregnancy; Progestins; Stroke; Young Adult | 2010 |
Weight and body fat changes in postpartum depot-medroxyprogesterone acetate users.
Topics: Adiposity; Adolescent; Adult; Body Composition; Body Mass Index; Contraceptive Agents, Female; Delayed-Action Preparations; Female; Humans; Medroxyprogesterone Acetate; Obesity; Ohio; Overweight; Postnatal Care; Prospective Studies; Reproducibility of Results; Risk; Sterilization, Tubal; Weight Gain; Young Adult | 2013 |
Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA).
Topics: Adolescent; Adult; Black People; Body Composition; Body Mass Index; Contraceptive Agents, Female; Feeding Behavior; Female; Humans; Interviews as Topic; Longitudinal Studies; Medroxyprogesterone Acetate; Obesity; Prospective Studies; Risk Factors; Weight Gain; White People | 2004 |
Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Nitriles; Obesity; Triazoles | 2004 |
Predictors of heart failure among women with coronary disease.
Topics: Aged; Atrial Fibrillation; Black or African American; Bundle-Branch Block; Cohort Studies; Comorbidity; Coronary Disease; Diabetes Mellitus; Estrogens, Conjugated (USP); Follow-Up Studies; Heart Failure; Hormone Replacement Therapy; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Diseases; Medroxyprogesterone Acetate; Middle Aged; Obesity; Postmenopause; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors | 2004 |
Transdermal hormone replacement therapy and Doppler findings in normal and overweight postmenopausal patients.
Topics: Administration, Cutaneous; Blood Viscosity; Body Mass Index; Cardiovascular Diseases; Endometrium; Estradiol; Estrogen Replacement Therapy; Female; Humans; Lipids; Medroxyprogesterone Acetate; Middle Aged; Obesity; Postmenopause; Pulsatile Flow; Risk Factors; Thromboxane B2; Triglycerides; Ultrasonography, Doppler, Color; Urinary Bladder; Vascular Resistance | 2004 |
The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
Topics: Aged; Body Mass Index; Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Metabolic Syndrome; Middle Aged; Neoplasms; Obesity; Postmenopause; Randomized Controlled Trials as Topic; Risk Factors; Women's Health | 2006 |
Clinical inquiries. What hormonal contraception is most effective for obese women?
Topics: Contraceptive Agents, Female; Desogestrel; Drug Combinations; Ethinyl Estradiol; Evidence-Based Medicine; Female; Humans; Medroxyprogesterone Acetate; Norgestrel; Obesity; Pregnancy; Pregnancy Rate; Risk Assessment | 2007 |
Effects of hormone replacement therapy and social stress on body fat distribution in surgically postmenopausal monkeys.
Topics: Adipose Tissue; Analysis of Variance; Animals; Anthropometry; Body Composition; Diet, Fat-Restricted; Dominance-Subordination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hierarchy, Social; Macaca; Medroxyprogesterone Acetate; Obesity; Ovariectomy; Postmenopause; Random Allocation; Stress, Psychological; Tomography, X-Ray Computed | 1999 |
Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women.
Topics: Cholesterol; Estradiol; Female; Glucose Tolerance Test; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Obesity; Triglycerides; Weight Loss | 1999 |
Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate.
Topics: Adolescent; Body Mass Index; Contraceptive Agents, Female; Female; Humans; Medical Records; Medroxyprogesterone Acetate; Obesity; Progesterone Congeners; Retrospective Studies; Risk Factors; Weight Gain | 2002 |
[Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Drug Evaluation; Drug Resistance; Drug Therapy, Combination; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Obesity; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Tamoxifen; Tegafur; Uterine Hemorrhage | 1989 |